// App-Quantinova.ai

213 : Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.

Researchers

Presenter

  • Vincenza Conteduca

Principal Investigators

  • Orazio Caffo

  • Lisa Derosa

  • Vincenzo Emanuele Chiuri

  • Matteo Santoni

  • Daniele Santini

  • Lucia Fratino

  • Francesca Maines

  • Sara Testoni

  • Ugo De Giorgi

  • Antonello Veccia

  • Elisabetta Petracci

Medical Centers

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, ItalyIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, ItalySanta Chiara Hospital, Trento, Italy

  • Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Division of Medical Oncology II, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy

  • Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy

  • Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I-GM Lancisi and G Salesi, Ancona, Italy

  • National Cancer Center CRO, Aviano, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Metabolic syndrome

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved